CDT Equity's Q2 10-Q Reveals Cash Dwindling to $747K, J.J. Astor Debt Defaults, and New Sarborg Dilution
CDT is trading near its 52-week low of $2.53 (15% above the low).
Summary
CDT Equity's Q2 10-Q shows cash down to $747K, missed debt payments leading to a $2.4M restructured J.J. Astor note, and a new Sarborg deal involving up to 12.1M pre-funded warrants.
Key Events · Earnings and Guidance · CDT
-
Cash Position Deteriorates
Cash and cash equivalents fell to $747,000 as of June 30, 2026, from $1.509 million at December 31, 2025, while the company reported a net loss of $8.7 million for the first half of 2026.
-
J.J. Astor Note Default and Restructuring
The company missed three weekly payments totaling $246,000 on its J.J. Astor convertible note. A July 31, 2026 amendment added a $378,000 restructuring premium, increasing the principal to $2.4 million, and raised the default interest rate from 19% to 24%.
-
Third Amendment Adds More Debt
On August 3, 2026, J.J. Astor advanced an additional $200,000, bringing the principal to approximately $2.5 million, and received warrants to purchase 37,500 shares at $7.20 per share.
-
New Sarborg Acquisition Dilutes Further
On July 30, 2026, the company agreed to acquire an additional 4.76% of Sarborg in exchange for pre-funded warrants to purchase up to 12,131,770 shares of common stock, pending shareholder approval.
Analysis · CDT · Life Sciences
CDT Equity's second-quarter report confirms the company is in a deepening cash crisis. Cash fell to $747,000 from $1.5 million at year-end, and the company missed three weekly payments on its J.J. Astor convertible note, triggering a restructuring that added a $378,000 premium and raised the default interest rate to 24%. A third amendment added another $200,000 advance and more warrants. The company also agreed to issue up to 12.1 million pre-funded warrants to buy more of Sarborg, a related party. With a going concern warning already in place, these developments show the company is relying on increasingly expensive and dilutive financing to stay afloat.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $2.53 to $3,700.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.